注射用血塞通联合双嘧达莫治疗冠心病心绞痛疗效观察及对患者免疫功能影响的研究

摘要

Objective To explore the efficacy of Xuesaitong injection combined with dipyridamole for treating angina pectoris and its in-fluence on the immunologic function in patients. Methods Eighty-two cases of angina pectoris patients were assigned into the control group(n = 41) and the treatment group(n = 41) by a randomized way. The patients were given aspirin and so on to perform the regular treatments. The control group was given dipyridamole,the treatment group was given Xuesaitong injection on the basis of control group. The clinic effects of two groups were compared. The daily angina frequency,duration and nitroglycerin dosage were observed. The levels of immunoglobulin(IgG,IgA,IgM) and peripheral blood T cell subsets(CD3 + ,CD4 + ,CD8 + and CD4 + / CD8 + ) were detected. The rates of adverse action were observed. Results In the treatment group,the obvious effective rate and the total effective rate were 65. 8％ and 92. 6％ ,significantly higher than that in the control group(P < 0. 05). The daily angina frequency,duration and nitroglycer-in dosage were(0. 91 ± 0. 12) d,(1. 93 ± 0. 36) min and(1. 21 ± 0. 36) mg in the treatment group,significantly lower than which in the control group(P < 0. 05). The levels of immunoglobulin(IgG,IgA,IgM) and peripheral blood T cell subsets(CD3 + ,CD4 + ,CD8 +and CD4 + / CD8 + ) were significantly higher in the treatment group than that in the control group(P < 0. 05). There were no serious ad-verse actions occurred in the patients. Conclusions The effect of Xuesaitong injection combined with dipyridamole for treating angina pectoris is affirmative and worth further study.%目的 探讨注射用血塞通联合双嘧达莫治疗冠心病心绞痛疗效及对患者免疫功能的影响.方法 选取82例冠心病心绞痛患者作为研究对象,采用随机数字表法将其均分为观察组及对照组.所有患者均给予阿司匹林、硝酸甘油等药物进行一般治疗,对照组在此基础上另口服给予双嘧达莫进行治疗,观察组患者在对照组治疗基础上再给予注射用血塞通治疗.观察两组患者的临床疗效;治疗后,对各组患者每天心绞痛发作次数、心绞痛发作持续时间及硝酸甘油用量进行观察;治疗前后,分别检测各组患者免疫球蛋白(IgG、IgA、IgM)及外周血T细胞亚群(CD3+、CD4+、CD8+和CD4+/CD8+)的水平;观察所有患者治疗期间不良反应发生情况.结果 观察组总有效率明显高于对照组(P<0.05);治疗后观察组心绞痛发作次数、持续时间和硝酸甘油用量分别为(0.91±0.12)次/天、(1.93±0.36)分钟/次及(1.21±0.36)mg,均明显优于对照组(P<0.05);治疗后,观察组免疫球蛋白和外周血T细胞亚群水平均明显高于对照组(P<0.05);治疗期间所有患者均未发生严重不良反应.结论 注射用血塞通联合双嘧达莫治疗冠心病心绞痛临床疗效较好,值得进行深入研究.